Trial reportClinical drug investigation2026
Comparative Sensory Evaluation of Pediatric Liquid Omeprazole Formulations Available in the UK.
Trial report in Clinical drug investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOmeprazole is a widely prescribed proton pump inhibitor used to treat gastroesophageal reflux disease and other acid-related disorders in children. Despite its clinical importance, the availability of licensed liquid formulations varies worldwide, often resulting in the use of extemporaneously compounded preparations. These liquid products have varying sensory characteristics that can influence patient acceptability.
methodsA randomized, single-blind sensory evaluation study was conducted with a panel of 30 adult volunteers (aged 24 ± 2.6 years; 77% female) to assess the palatability of six omeprazole liquid formulations available in the UK. Participants rated taste, aftertaste, smell, and mouthfeel aversiveness using a visual analog scale, overall acceptability using a 5-point facial hedonic scale, and provided qualitative feedback.
resultsThe compounded 8.4% sodium bicarbonate suspension had a significantly more aversive taste (mean ± standard deviation: 74 ± 31; median [interquartile range]: 83 [63-100]) and aftertaste (55 ± 33; 61 [23-80]) compared with all licensed formulations (p < 0.001), with bitterness being a prominent attribute. The licensed menthol-flavored 10-mg/15-mL oral solution received the lowest taste aversiveness rating (17 ± 23; 6 [1-19]), and the highest overall acceptability. Other licensed formulations were generally rated as mild to moderately aversive, with some irritating or burning sensations also reported.
conclusionsA sensory analysis revealed clear differences between compounded and licensed omeprazole formulations, highlighting the importance of developing and prescribing palatable age-appropriate formulations for pediatric populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.